These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23604466)

  • 1. Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.
    Lee SH; Kim N; Kim SJ; Song J; Gong YD; Kim SY
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1279-94. PubMed ID: 23604466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition.
    Jeong KC; Ahn KO; Lee BI; Lee CH; Kim SY
    J Cancer Res Clin Oncol; 2010 Jan; 136(1):143-50. PubMed ID: 19655169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
    Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY
    Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival.
    Kim SJ; Kim KH; Ahn ER; Yoo BC; Kim SY
    Amino Acids; 2013 Jan; 44(1):73-80. PubMed ID: 21960143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
    Hitomi K; Ikura K; Maki M
    Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
    Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
    J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
    Kim DS; Park SS; Nam BH; Kim IH; Kim SY
    Cancer Res; 2006 Nov; 66(22):10936-43. PubMed ID: 17108131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia.
    Lee J; Kim YS; Choi DH; Bang MS; Han TR; Joh TH; Kim SY
    J Biol Chem; 2004 Dec; 279(51):53725-35. PubMed ID: 15471861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
    Kim N; Kwak SH; Lee SH; Juvekar V; Lee BI; Ahn HC; Kim SY; Gong YD
    Org Biomol Chem; 2014 Jul; 12(27):4932-40. PubMed ID: 24879506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
    Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
    Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2.
    Park KS; Kim DS; Ko C; Lee SJ; Oh SH; Kim SY
    Front Biosci (Elite Ed); 2011 Jan; 3(1):341-54. PubMed ID: 21196314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinnamoyl inhibitors of tissue transglutaminase.
    Pardin C; Pelletier JN; Lubell WD; Keillor JW
    J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.
    Hauser C; Wodtke R; Löser R; Pietsch M
    Amino Acids; 2017 Mar; 49(3):567-583. PubMed ID: 26886924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors.
    Kim DS; Park KS; Kim SY
    Front Biosci (Landmark Ed); 2009 Jan; 14(7):2514-21. PubMed ID: 19273216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
    Case A; Stein RL
    Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors.
    Case A; Ni J; Yeh LA; Stein RL
    Anal Biochem; 2005 Mar; 338(2):237-44. PubMed ID: 15745743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.
    Kim DY; Park BS; Hong GU; Lee BJ; Park JW; Kim SY; Ro JY
    Br J Pharmacol; 2011 Jan; 162(1):210-25. PubMed ID: 20840469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.
    Kim DS; Han BG; Park KS; Lee BI; Kim SY; Bae CD
    Biochem Biophys Res Commun; 2010 Aug; 399(2):300-6. PubMed ID: 20659425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells.
    Kim JM; Voll RE; Ko C; Kim DS; Park KS; Kim SY
    J Mol Biol; 2008 Dec; 384(4):756-65. PubMed ID: 18950638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
    Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
    Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.